Impact of metagenomic next-generation sequencing on clinical decision-making at an academic medical center, a retrospective study, Iowa, 2020-2022

Michael Olthoff; Takaaki Kobayashi; Meredith G Parsons; Bradley Ford; Kunatum Prasidthrathsint; Lemuel Non; Jorge L Salinas; Daniel J Diekema; Dilek Ince

doi:10.1017/ash.2024.31

Impact of metagenomic next-generation sequencing on clinical decision-making at an academic medical center, a retrospective study, Iowa, 2020-2022

Antimicrob Steward Healthc Epidemiol. 2024 Mar 27;4(1):e39. doi: 10.1017/ash.2024.31. eCollection 2024.

Authors

Michael Olthoff¹, Takaaki Kobayashi^{1

2}, Meredith G Parsons³, Bradley Ford³, Kunatum Prasidthrathsint^{1

3}, Lemuel Non¹, Jorge L Salinas⁴, Daniel J Diekema^{1

5}, Dilek Ince¹

Affiliations

¹ Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
² Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
³ Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
⁴ Department of Internal Medicine, Stanford University, Stanford, CA, USA.
⁵ Department of Medicine, Maine Medical Center, Portland, ME, USA.

Abstract

We assessed the impact of metagenomic next-generation sequencing (mNGS) on patient care using previously established criteria. Among 37 patients receiving mNGS testing, 16% showed results that had a positive clinical impact. While mNGS results may offer valuable supplementary information, results should be interpreted within the broader clinical context and evaluation.